Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target

Citizens maintained their Market Outperform rating on Compass Therapeutics's stock with a price target of $4.00.The price target implies an upside of 222.6% from the Sep 22 close of $1.24.Key takeaways from the analyst notePositive Pipeline Developments: Compass Therapeutics is advancing its clinic…